Skip to main content
. 2017 Jul 3;130(9):1125–1131. doi: 10.1182/blood-2017-05-783225

Figure 2.

Figure 2.

Kaplan-Meier survival curves showing survival after ruxolitinib discontinuation. Comparison of survival after discontinuation by platelet counts at (A) baseline and (B) follow-up. (C) Comparison of survival after ruxolitinib discontinuation in those with and without clonal evolution. Cum, cumulative; FU, follow-up; HR, hazard ratio.